ArticleExperimental and therapeutic medicine2019
Tanshinone IIA attenuates estradiol-induced polycystic ovarian syndrome in mice by ameliorating FSHR expression in the ovary.
Article in Experimental and therapeutic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 23 citations in OpenAlex.
- Cholesterol and testosterone dynamics in a polycystic ovary syndrome animal model.Open veterinary journal · 2026Article
- Huatan Tongmai Yin regulates RFRP-3 to intervene in the "microbe-gut-HPO axis" to treat PCOS-IR rats.American journal of translational research · 2025Article
- Natural compounds in the management of polycystic ovary syndrome: a comprehensive review of hormonal regulation and therapeutic potential.Frontiers in nutrition · 2025Review
- Exploring the therapeutic mechanisms of Yikang decoction in polycystic ovary syndrome: an integration of GEO datasets, network pharmacology, and molecular dynamics simulations.Frontiers in medicine · 2024Article
- Tanshinone ⅡA participates in the treatment of endometriosis by regulating adhesion, invasion, angiogenesis and inhibition of PI3K/Akt/mTOR signaling pathway.Molecular medicine reports · 2023Article
- Effects of natural products on polycystic ovary syndrome: From traditional medicine to modern drug discovery.Heliyon · 2023Article
- Orexin antagonism and substance-P: Effects and interactions on polycystic ovary syndrome in the wistar rats.Journal of ovarian research · 2023Article
- Tanshinone IIA enhances the ovarian reserve and attenuates ovarian oxidative stress in aged mice.Veterinary medicine and science · 2022Article
- Establishment and characterization of a PCOS and a normal human granulosa cell line.Cytotechnology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tanshinone IIA (TSIIA) is a major component of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.